The United Kingdom’s National Health Service (NHS) has decided to pause the prescription of cross-sex hormones to individuals under the age of 18. This policy shift, effective immediately, means that young people seeking treatment for gender dysphoria will now have to wait until they turn 18 years old to access these medications. Previously, individuals aged 16 and over could begin hormone treatment, but this change comes in light of concerns raised by a recent review regarding the adequacy of existing research on the benefits and potential side effects of these treatments.
The pause follows the Cass Review, which highlighted that prior studies did not provide robust evidence supporting the use of cross-sex hormones in this age group. The review concluded that the existing body of research was “really weak,” necessitating a precautionary approach to prescribing such treatments to adolescents. This decision adds to previous restrictions, as the UK government has already limited access to puberty blockers for those under 18.
Internationally, similar actions have been taken. Queensland, Australia, has announced a ban on medical treatment for transgender youth until 2031, while New Zealand has also moved to limit access to puberty blockers. These developments reflect ongoing debates about how best to support transgender youth in medical settings.
The NHS estimates that only a small number of teenagers will be affected by this policy change, and those already undergoing hormone treatment will be allowed to continue. The NHS has also initiated a new consultation process to establish long-term guidance on prescribing these medications. The report did not conclude that the treatments were inherently harmful or beneficial; instead, it emphasized the lack of sufficient evidence to make informed decisions at this time.
In a statement to the BBC, Professor James Palmer, National Medical Director for Specialised Services at NHS England, said, “The NHS has exercised extreme caution when considering starting young people on this treatment.” He described the review process as “exceptionally thorough and complex,” noting that it established that the available evidence does not support the continued use of masculinising or feminising hormones for treating young people under 18.
The rights group TransLucent expressed its discontent with the announcement, calling it another act of discrimination against transgender youth. The organization indicated that it would evaluate the government’s decision before formulating a response and has not ruled out pursuing legal action against the NHS.
As this policy unfolds, it raises significant implications for the support and treatment available to young people navigating gender dysphoria in the UK. The NHS aims to ensure that any future guidance on hormone treatment is grounded in solid evidence, reflecting a cautious approach to the complexities surrounding transgender healthcare.
